TG Therapeutics, Inc. (TGTX)
Develops cancer and autoimmune drugs targeting B-cells to treat multiple sclerosis and blood disorders.
$54.87-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+56.7%
The outlook
TGTX is trading near the upper end of its 52-week range, above both its 50- and 200-day moving averages, reflecting upward momentum. Analyst coverage is strong, with a consensus of "Strong Buy" and an average price target sitting roughly 17% above the current price. The stock's trailing P/E of 19.2 sits in moderate territory.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 7 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +17% vs current price
Analyst price target
~12-month · 7 analysts$64.00average target+16.6% vs now
Now $54.87
Low $20.00High $83.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.40B
52-wk high
$59.30
52-wk low
$25.28
50-day avg
$48.83
200-day avg
$36.30
Trailing P/E
19.2